You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Osteoporosis

Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

  • Technology appraisal guidance
  • Reference number: TA161
  • Published:  27 October 2008
  • Last updated:  07 February 2018
  • Guidance
  • Tools and resources
  • History

Osteoporosis - secondary prevention including strontium ranelate: Court Order, Memorandum of Understanding, background information and matrix of stakeholders for this reconsideration

  • Osteoporosis - secondary prevention including strontium ranelate: Court Order and Memorandum of Understanding

  • Osteoporosis - secondary prevention including strontium ranelate: background to the reconsideration of strontium ranelate

  • Osteoporosis - secondary prevention including strontium ranelate: history of the appraisal development

  • Osteoporosis - secondary prevention including strontium ranelate: guidance for the Committee on the reconsideration of strontium ranelate

  • Osteoporosis - secondary prevention including strontium ranelate: final matrix of Consultees and Commentators for the reconsideration of strontium ranelate


This page was last updated: 06 December 2010

Back to top